Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

VernacularTitle:驱动基因阴性非小细胞肺癌二线治疗中国专家共识
Author: Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology ; ZHOU CAICUN
Keywords: Lung neoplasms; Immunotherapy; Anti-angiogenic drugs; Negative driver gene mutations; Expert consensus
From: Chinese Journal of Lung Cancer 2024;27(2):81-87
CountryChina
Language:Chinese
Abstract: For advanced non-small cell lung cancer(NSCLC)patients with negative driver gene mutations,chemo-therapy has always been the standard treatment option,and immune checkpoint inhibitors(ICIs)provide other treatment op-tion for these patients.At present,the first-line treatment can choose chemotherapy,anti-angiogenic drugs or immunotherapy.Although the initial treatment can achieve a certain clinical curative effect,disease progression or treatment failure is eventually unavoidable.The second-line and subsequent treatments have poor efficacy and more effective drugs are needed clinically.An expert panel of respiratory medicine,pathology and medical oncology organized by Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology conducted an in-depth discussion on evidences of clinical studies for second-line treatment of NSCLC patients with negative driver gene mutations,aiming to provide guidances for Chinese clini-cians in choosing second-line treatment for NSCLC patients with negative driver gene mutations.